Diagnosis | Likely organism | Initial therapy | Level of evidence | Strength of recommendation |
---|---|---|---|---|
Community-acquired localized peritonitis (e.g. recently perforated appendicitis) | Enterobacteriaceae Enterococci | Cephalosporin group 2 /3a + metronidazole | 1/1 | A/A |
 | Anaerobes | Aminopenicillin/BLI | 1 | A |
 |  | Acylaminopenicillin/BLI | 1 | A |
 |  | Ciprofloxacin* + Met. | 1 | B |
Community-acquired diffuse peritonitis +- risk factors (e.g. perforated colonic carcinoma) | Enterobacteriaceae Enterococci | Cephalosporin group 3a + metronidazole | 1 | A |
 | Anaerobes | Acylaminopenicillin/BLI | 1 | A |
 |  | Imipenem-Cilastatin | 1 | A |
 |  | Meropenem | 1 | A |
 |  | Doripenem | 1 | A |
 |  | Ertapenem | 1 | A |
 |  | Moxifloxacin | 1 | A |
 |  | Tigecycline | 1 | B |
 |  | Cefepime | 1 | B |
 |  | Ciprofloxacin*+ Met. | 1 | B |
 |  | Levofloxacin* + Met. | 1 | B |
Nosocomial postoperative, post-traumatic or post-interventional diffuse peritonitis (e.g. anastomotic leakage following ileotransversostomy) | Enterobacteriaceae | Imipenem-Cilastatin | 1 | A |
 | Enterococci | Meropenem | 1 | A |
 | Anaerobes | Doripenem | 1 | A |
 | Staphylococci | Acylaminopenicillin/BLI | 1 | A |
 |  | Ertapenem# | 1 | A |
 |  | Tigecycline# | 2 | A |
 |  | Moxifloxacin | 1 | B |
 | MRSA VRE ESBL | see Table 5 |  |  |
 | Candida spp. | see Table 6 |  |  |